Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective
- PMID: 14526384
- DOI: 10.1038/nrd1201
Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective
Abstract
Highly active antiretroviral therapy (HAART) regimes based on nucleoside reverse transcriptase inhibitors (NRTIs) have revolutionized the treatment of AIDS in recent years. Although HAART can successfully suppress viral replication in the long term, it is not without significant toxicity, which can seriously compromise treatment effectiveness. A major toxicity that has been recognized for more than a decade is NRTI-related mitochondrial toxicity, which manifests as serious side effects such as hepatic failure and lactic acidosis. However, a lack of understanding of the mechanisms underlying mitochondrial toxicity has hampered efforts to develop novel drugs with better side-effect profiles. This review characterizes the pharmacological mechanisms and pathways that are involved in mitochondrial dysfunction caused by NRTIs, and suggests opportunities for future pharmacological research.
Similar articles
-
A brief overview of mechanisms of mitochondrial toxicity from NRTIs.Environ Mol Mutagen. 2007 Apr-May;48(3-4):166-72. doi: 10.1002/em.20223. Environ Mol Mutagen. 2007. PMID: 16758472 Review.
-
Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.Clin Ther. 2000 Jun;22(6):685-708. doi: 10.1016/S0149-2918(00)90004-3. Clin Ther. 2000. PMID: 10929917 Review.
-
Cell culture models for the investigation of NRTI-induced mitochondrial toxicity. Relevance for the prediction of clinical toxicity.Toxicol In Vitro. 2006 Aug;20(5):535-46. doi: 10.1016/j.tiv.2005.11.007. Epub 2006 Jan 10. Toxicol In Vitro. 2006. PMID: 16406476 Review.
-
Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity.Clin Ther. 2000 Aug;22(8):911-36; discussion 898. doi: 10.1016/S0149-2918(00)80064-8. Clin Ther. 2000. PMID: 10972629
-
Highly active antiretroviral therapy (HAART)-associated lactic acidosis: in vitro effects of combination of nucleoside analogues and protease inhibitors on mitochondrial function and lactic acid production.Cell Mol Biol (Noisy-le-grand). 2003 Dec;49(8):1205-11. Cell Mol Biol (Noisy-le-grand). 2003. PMID: 14983988
Cited by
-
Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES.AIDS Res Hum Retroviruses. 2013 Feb;29(2):350-8. doi: 10.1089/aid.2012.0278. Epub 2012 Dec 5. AIDS Res Hum Retroviruses. 2013. PMID: 23039030 Free PMC article. Clinical Trial.
-
Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition.Antimicrob Agents Chemother. 2008 Feb;52(2):598-605. doi: 10.1128/AAC.01122-07. Epub 2007 Dec 3. Antimicrob Agents Chemother. 2008. PMID: 18056280 Free PMC article.
-
Integration of High-Throughput Imaging and Multiparametric Metabolic Profiling Reveals a Mitochondrial Mechanism of Tenofovir Toxicity.Function (Oxf). 2022 Dec 24;4(1):zqac065. doi: 10.1093/function/zqac065. eCollection 2023. Function (Oxf). 2022. PMID: 36654930 Free PMC article.
-
The Role of Transforming Growth Factor Beta-1 in the Progression of HIV/AIDS and Development of Non-AIDS-Defining Fibrotic Disorders.Front Immunol. 2017 Nov 2;8:1461. doi: 10.3389/fimmu.2017.01461. eCollection 2017. Front Immunol. 2017. PMID: 29163528 Free PMC article. Review.
-
Cardiac-targeted transgenic mutant mitochondrial enzymes: mtDNA defects, antiretroviral toxicity and cardiomyopathy.Cardiovasc Toxicol. 2008 Summer;8(2):57-69. doi: 10.1007/s12012-008-9015-1. Epub 2008 Apr 30. Cardiovasc Toxicol. 2008. PMID: 18446447 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical